BR112016024494A8 - análogo de peptídeo e seu uso - Google Patents

análogo de peptídeo e seu uso

Info

Publication number
BR112016024494A8
BR112016024494A8 BR112016024494A BR112016024494A BR112016024494A8 BR 112016024494 A8 BR112016024494 A8 BR 112016024494A8 BR 112016024494 A BR112016024494 A BR 112016024494A BR 112016024494 A BR112016024494 A BR 112016024494A BR 112016024494 A8 BR112016024494 A8 BR 112016024494A8
Authority
BR
Brazil
Prior art keywords
peptide analogue
peptide
analogue
variants
amino acid
Prior art date
Application number
BR112016024494A
Other languages
English (en)
Other versions
BR112016024494B1 (pt
BR112016024494A2 (pt
Inventor
Boesen Thomas
Original Assignee
Txp Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Txp Pharma Gmbh filed Critical Txp Pharma Gmbh
Publication of BR112016024494A2 publication Critical patent/BR112016024494A2/pt
Publication of BR112016024494A8 publication Critical patent/BR112016024494A8/pt
Publication of BR112016024494B1 publication Critical patent/BR112016024494B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

análogo de peptídeo e seu uso a presente invenção refere-se a análogos de peptídeo que compreendem uma ou mais sondas de aminoácidos ramificados e um peptídeo, nativo ou suas variantes.
BR112016024494-0A 2014-04-22 2015-04-21 Análogo de peptídeo e seu uso BR112016024494B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982709P 2014-04-22 2014-04-22
US61/982,709 2014-04-22
PCT/IB2015/000553 WO2015162485A1 (en) 2014-04-22 2015-04-21 Peptide analogues with branched amino acid probe(s)

Publications (3)

Publication Number Publication Date
BR112016024494A2 BR112016024494A2 (pt) 2017-08-15
BR112016024494A8 true BR112016024494A8 (pt) 2021-07-06
BR112016024494B1 BR112016024494B1 (pt) 2024-02-06

Family

ID=53524914

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024494-0A BR112016024494B1 (pt) 2014-04-22 2015-04-21 Análogo de peptídeo e seu uso

Country Status (12)

Country Link
US (3) US9950027B2 (pt)
EP (2) EP3838285A1 (pt)
JP (2) JP2017513875A (pt)
CN (1) CN106232623A (pt)
AU (1) AU2015249540B2 (pt)
BR (1) BR112016024494B1 (pt)
CA (1) CA2943458A1 (pt)
DK (1) DK3134105T3 (pt)
ES (1) ES2854353T3 (pt)
HU (1) HUE052977T2 (pt)
RU (1) RU2016142145A (pt)
WO (1) WO2015162485A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2944650A1 (en) 2012-10-19 2015-11-18 TXP Pharma GmbH Alpha- and gamma- MSH analogues
EP3838285A1 (en) 2014-04-22 2021-06-23 TXP Pharma GmbH Peptide analogues with branched amino acid probe(s)
TWI715755B (zh) * 2016-05-02 2021-01-11 愛爾蘭商滿捷特科技公司 用於高速列印之單色噴墨列印頭
RU2678987C2 (ru) * 2017-04-28 2019-02-05 Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" Пептид для лечения болезни альцгеймера
MX2020008096A (es) * 2018-01-31 2020-09-24 Sanofi Sa Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.
CN108395484A (zh) * 2018-03-15 2018-08-14 华东理工大学 支链氨基酸荧光探针及其应用
CN109232747B (zh) * 2018-09-26 2019-06-11 哈尔滨工业大学 强啡肽a(1-8)与神经降压素(8-13)相偶联的环化杂合肽及其合成方法和应用
CN109283341A (zh) * 2018-10-17 2019-01-29 北京市心肺血管疾病研究所 一组预测心肌梗死患者的pci术后预后的生物标志物
WO2020198604A1 (en) * 2019-03-28 2020-10-01 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of treating and preventing systemic complications of acute illness
CN114573663B (zh) * 2019-08-27 2023-08-11 广东菲鹏生物有限公司 瓜氨酸肽及其应用、类风湿关节炎的检测试剂与试剂盒
CN116390938A (zh) 2020-08-12 2023-07-04 Txp制药股份有限公司 毒蜥外泌肽-4类似物
AU2021327733A1 (en) 2020-08-21 2023-04-20 Resother Pharma A/S Annexin a1 n-terminal peptide formulations and methods
WO2022159555A1 (en) * 2021-01-20 2022-07-28 The Trustees Of Columbia University In The City Of New York Methods for treating graft-versus-host disease using glp-2 agonists and analogues thereof
US20220370624A1 (en) * 2021-05-05 2022-11-24 Arcturus Therapeutics, Inc. Lipid compositions comprising peptide-lipid conjugates
CN113238060B (zh) * 2021-05-08 2022-10-11 迈克生物股份有限公司 用于预测或诊断心肌炎的试剂盒
WO2023161323A1 (en) 2022-02-23 2023-08-31 Resother Pharma A/S Annexin a1-derived polypeptide analogues
CN115925784B (zh) * 2022-11-24 2023-06-09 北京工商大学 一种丹磺酰类铜离子荧光探针、制备方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
CA2275442A1 (en) 1996-12-17 1998-06-25 Quadrant Holdings Cambridge Limited Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
AU776514B2 (en) * 1998-08-10 2004-09-09 General Hospital Corporation, The Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
CA2415938A1 (en) 2000-07-14 2002-01-24 Zycos Inc. Alpha-msh related compounds and methods of use
CN102174102A (zh) * 2003-05-15 2011-09-07 塔夫茨大学信托人 肽和多肽药物的稳定类似物
US7169303B2 (en) 2003-05-28 2007-01-30 Hemocleanse Technologies, Llc Sorbent reactor for extracorporeal blood treatment systems, peritoneal dialysis systems, and other body fluid treatment systems
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
CA3228910A1 (en) 2005-07-08 2007-01-18 Ipsen Pharma S.A.S Melanocortin receptor ligands
DK1919947T3 (da) * 2005-08-26 2013-03-18 Abbvie Inc Terapeutisk aktive alfa-MSH analoger
EP2944650A1 (en) 2012-10-19 2015-11-18 TXP Pharma GmbH Alpha- and gamma- MSH analogues
CN103536912B (zh) * 2013-09-30 2015-05-13 重庆理工大学 一种猪圆环病毒2型表位肽疫苗及其制备方法
WO2015162486A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues
WO2015162483A1 (en) 2014-04-22 2015-10-29 Txp Pharma Gmbh Alpha- and gamma-msh analogues
EP3838285A1 (en) 2014-04-22 2021-06-23 TXP Pharma GmbH Peptide analogues with branched amino acid probe(s)

Also Published As

Publication number Publication date
US20150297671A1 (en) 2015-10-22
RU2016142145A (ru) 2018-05-22
CN106232623A (zh) 2016-12-14
EP3134105A1 (en) 2017-03-01
US20220133839A1 (en) 2022-05-05
JP7253812B2 (ja) 2023-04-07
DK3134105T3 (da) 2021-02-22
AU2015249540B2 (en) 2019-08-22
HUE052977T2 (hu) 2021-06-28
BR112016024494B1 (pt) 2024-02-06
CA2943458A1 (en) 2015-10-29
AU2015249540A1 (en) 2016-11-17
US20190030115A1 (en) 2019-01-31
WO2015162485A1 (en) 2015-10-29
US11141455B2 (en) 2021-10-12
JP2017513875A (ja) 2017-06-01
RU2016142145A3 (pt) 2018-12-12
EP3134105B1 (en) 2020-11-18
JP2020172496A (ja) 2020-10-22
EP3838285A1 (en) 2021-06-23
ES2854353T3 (es) 2021-09-21
EP3134105B8 (en) 2020-12-30
US9950027B2 (en) 2018-04-24
BR112016024494A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
BR112016024494A8 (pt) análogo de peptídeo e seu uso
CL2018002081A1 (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
BR112017027132A2 (pt) reguladores do nrf2
BR112017025499A2 (pt) benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa
BR112017027137A2 (pt) reguladores de nrf2
CL2016002772A1 (es) Composiciones de insulina de rápida acción
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
BR112017009623A2 (pt) composição de limpeza
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
SV2018005643A (es) Composiciones de insulina de rapida accion
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
BR112018076215A2 (pt) partículas e composições de nicotina
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
BR112018072539A2 (pt) composições de epinefrina de administração aumentada
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
BR112019005637A2 (pt) análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
CL2018002645A1 (es) Sulfonamidas sustituidas para controlar plagas animales
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CO2017011295A2 (es) Piroglutamato de vortioxetina
BR112017008952A2 (pt) métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2015, OBSERVADAS AS CONDICOES LEGAIS